Clofazamine for the Treatment of Mycobacterium Avium Intracellulare(MAI)

This protocol is an single patient IND to provide clofazamine to treat one patient who has MAI and is resistant to or can not tolerate standard of care. The drug is not otherwise available.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infection, Mycobacterium Avium-Intracellulare Actinomycetales Infections Bacterial Infections Bacterial Infections and Mycoses Gram-Positive Bacterial Infections Infections Mycobacterium Infections Mycobacterium Infections, Nontuberculous Mycobacterium avium-intracellulare Infection

Sex eligibility

Female

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Treatment of one patient with MAI

Exclusion criteria

No other patients will be treated

Sponsors and collaborators

Lead sponsor

Yale University

Other

Registry information

Official study title

IND for One Patient to Receive Clofazamine for Treatment of MAI

Important dates

Study start: 2006
Primary completion: 2007
Study completion: 2007
First posted: Apr 3, 2008
Registry last updated: Apr 3, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed